Investing.com - BioCryst reported on Tuesday third quarter earnings that beat analysts' forecasts and revenue that topped expectations.
BioCryst announced earnings per share of $-0.23 on revenue of $75.83M. Analysts polled by Investing.com EPS of $-0.27 on revenue of $75.5M.
BioCryst 's are down 10% and is trading at $12.44 , still down 37.77% from its 52 week high of $19.99 set on Wednesday, February 16, 2022.
BioCryst follows other major Healthcare sector earnings this month
BioCryst's report follows an earnings beat by UnitedHealth on Friday, October 14, 2022, who reported EPS of $5.79 on revenue of $80.9B, EPS of $5.43 on revenue of $80.52B.
J&J had beat expectations on Tuesday, October 18, 2022 with third quarter EPS of $2.55 on revenue of $23.79B, for EPS of $2.52 on revenue of $23.46B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar